New europium MRI contrast agents to image low-oxygen areas in the body
Enabling systemic delivery of europium-containing contrast agents for magnetic resonance imaging
Researchers are creating intravenously delivered europium-based MRI contrast agents to help find low-oxygen (hypoxic) areas in cancers and other diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-11330176 on NIH RePORTER |
What this research studies
This project focuses on developing phosphonate-containing europium(II) compounds that can be carried safely through the bloodstream for MRI. The team is working to increase how long the agents stay in blood and to boost their MRI signal strength so they can reliably reveal hypoxic tissue. The work builds on an earlier molecule the team made that showed blood persistence, and now aims to modify the chemical arms to improve performance. If successful, these probes could be used across cancers and other conditions where low oxygen affects disease and treatment.
Who could benefit from this research
Good fit: People with cancers or other conditions where tissue hypoxia matters (for example some kidney, liver, or brain conditions) would be the most relevant candidates for future imaging using these agents.
Not a fit: Patients without hypoxia-related conditions, those who cannot have MRI, or those with severe kidney failure that prevents contrast use may not benefit from this work.
Why it matters
Potential benefit: If successful, the agents could help doctors detect and map low-oxygen regions in tumors and other organs to guide diagnosis and treatment choices.
How similar studies have performed: Other hypoxia-sensitive MRI approaches exist, but systemically delivered europium(II) agents are a recent development and the team's initial molecule showed promise though broader clinical success is still unproven.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Allen, Matthew J — Wayne State University
- Study coordinator: Allen, Matthew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.